Genetic susceptibility in solvent induced neurobehavioral effects.
The aim of this investigation was to study the influence of genetic polymorphisms of biotransformation enzymes and dopamine receptors on neurobehavioral effects in referents (n = 53), solvent-workers (n = 144), and chronic toxic encephalopathy (CTE) patients (n = 33). All participants were interviewed for exposure data and confounding factors and underwent a clinical examination. Neurobehavioral complaints (neurotoxicity symptom checklist-60) and effects [simple reaction time (SRT), symbol digit substitution (SDS), hand-eye coordination (HEC), and digit span backwards (DSB)] were evaluated with a computer assisted test battery. The following genotypes were determined: GSTM1, GSTT1, GSTP1, DRD2 Taq1A, DRD2 Taq1B, and DRD2-141Cdel. Neurotoxic effects and complaints were significantly higher in CTE patients and were related to both duration and level of exposure. An equal distribution of genotypes was found between all groups. Logistic regression analysis revealed that GSTT1 was negatively associated with sleep and sensorimotor complaints. GSTM1 had a protecting influence on the relationship between logDSB and the cumulative exposure index and between logSRT and cumulative exposure index and degree of exposure, respectively. This effect was also found when correcting for age, education level, alcohol consumption, and smoking. DRD2-141Cdel polymorphisms had a negative influence on the relationship between logSDS and the total exposure time. GSTT1 might be protective against sleep and sensorimotor complaints, whereas GSTM1 seems to decrease sustained attention and short-term memory problems in relation to solvent exposure. Individuals possessing DRD2-141Cdel variant experienced more visuomotor problems.
Godderis
L
L
Department of Occupational, Environmental and Insurance Medicine, Katholieke Universiteit Leuven, Kapucijnenvoer 35/5, Leuven, 3000, Belgium. lode.godderis@med.kuleuven.be
Maertens
N
N
de Gelder
V
V
De Lamper
A
A
De Ruyck
K
K
Vernimmen
M
M
Bulterys
S
S
Moens
G
G
Thierens
H
H
Viaene
M K
MK
D000328:Adult; D003430:Cross-Sectional Studies; D003936:Diagnosis, Computer-Assisted; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005982:Glutathione Transferase / Q000235:genetics*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008433:Mathematics; D008875:Middle Aged; D009460:Neurologic Examination / Q000379:methods; D009483:Neuropsychological Tests; D020258:Neurotoxicity Syndromes / Q000209:etiology* / Q000235:genetics*; D016273:Occupational Exposure; D011110:Polymorphism, Genetic / Q000235:genetics*; D011930:Reaction Time / Q000235:genetics; D017448:Receptors, Dopamine D2 / Q000235:genetics*; D012907:Smoking; D012997:Solvents / Q000633:toxicity*; D018709:Statistics, Nonparametric; D011795:Surveys and Questionnaires
D017448:Receptors, Dopamine D2; D012997:Solvents; C413545:glutathione S-transferase T1; D005982:Glutathione Transferase
Anal Biochem. 1996 Apr 5;236(1):184-6
8619490
Scand J Work Environ Health. 1996 Oct;22(5):360-3
8923609
Occup Environ Med. 2006 Mar;63(3):221-6, 179
16497867
IARC Sci Publ. 1997;(142):251-64
9354924
QJM. 2002 Jun;95(6):379-87
12037246
Occup Environ Med. 2007 Oct;64(10):673-80
17449559
Mov Disord. 2003 May;18(5):593-5
12722176
J Neurol. 1999 Mar;246(3):198-206
10323318
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):1038-42
16702390
Scand J Work Environ Health. 1990;16 Suppl 1:17-25
2189216
Neurotoxicology. 2000 Oct;21(5):659-65
11130269
Eur J Nucl Med. 1999 Feb;26(2):171-82
9933352
Int J Hyg Environ Health. 2006 Mar;209(2):139-50
16503300
Pharmacogenomics. 2000 Aug;1(3):309-33
11256581
Neurotoxicology. 1999 Feb;20(1):7-16
10091854
Int Arch Occup Environ Health. 1997;70(3):180-6
9298400
Environ Mol Mutagen. 2004;44(4):293-303
15468052
Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20552-7
18077373
Neurotox Res. 2007 Jan;11(1):61-72
17449449
Eur Psychiatry. 2002 Mar;17(1):17-23
11918988
Ann N Y Acad Sci. 2008;1129:200-12
18591481
Lancet. 1997 Apr 26;349(9060):1239-43
9130958
Environ Health Perspect. 1991 Jan;90:195-8
2050061
Ind Health. 1994;32(3):145-64
7698903
Neurosci Behav Physiol. 2003 Mar;33(3):223-5
12762588
Neurotoxicology. 2003 Aug;24(4-5):491-501
12900062
Toxicol Ind Health. 2002 Jul;18(6):289-96
14992466
Pharmacogenetics. 2000 Dec;10(9):781-8
11191882
Toxicol Ind Health. 2006 Aug;22(7):281-9
17022435
Ann Neurol. 2008 May;63(5):572-80
18412121
Pharmacogenetics. 2002 Dec;12(9):691-702
12464798
Neuroscience. 2009 Nov 24;164(1):131-40
19393722
Toxicology. 2003 Apr 15;186(1-2):131-41
12604177
Mol Psychiatry. 2007 May;12(5):454-61
17453061
Neuropsychopharmacology. 2006 Jan;31(1):231-42
16123753
Hum Mol Genet. 1997 Apr;6(4):577-82
9097961
Toxicology. 2006 Feb 15;219(1-3):220-9
16386346
Occup Environ Med. 2001 Feb;58(2):103-12
11160988